Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any retinitis pigmentosa in which the cause of the disease is a mutation in the SEMA4A gene.
Features include: Nyctalopia, Blindness, Reduced visual acuity, and Rod-cone dystrophy.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 1 | Blindness |
SEMA4A function has not been fully characterized.
Retinitis pigmentosa 35 is associated with mutations in the SEMA4A gene on chromosome 1.
Genetic testing for SEMA4A is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for retinitis pigmentosa 35 has been reported in the published literature.
No clinical trials have been registered for retinitis pigmentosa 35.
14 publications have been identified in PubMed for retinitis pigmentosa 35. Research spans Basic Science / Preclinical (29%), Epidemiology / Natural History (29%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 | 29% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 5:36 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
4 |
29% |
Testing and diagnosis research | 2 | 14% |
Patient case studies | 2 | 14% |
Other research | 1 | 7% |
New treatment approaches | 1 | 7% |
Chandler LC (2026). [PMID: 41380951](https://pubmed.ncbi.nlm.nih.gov/41380951/). *Exp Eye Res*. [Basic Science / Preclinical]
Karuntu JS (2025). [PMID: 39665295](https://pubmed.ncbi.nlm.nih.gov/39665295/). *Acta Ophthalmol*. [Epidemiology / Natural History]
Fu Y (2025). [PMID: 40064881](https://pubmed.ncbi.nlm.nih.gov/40064881/). *Nat Commun*. [Basic Science / Preclinical]
Heyang M (2025). [PMID: 39103200](https://pubmed.ncbi.nlm.nih.gov/39103200/). *Br J Ophthalmol*. [Epidemiology / Natural History]
Antropoli A (2025). [PMID: 38602021](https://pubmed.ncbi.nlm.nih.gov/38602021/). *Eur J Ophthalmol*. [Epidemiology / Natural History]
Chiu HI (2025). [PMID: 40335823](https://pubmed.ncbi.nlm.nih.gov/40335823/). *Ophthalmol Ther*. [Epidemiology / Natural History]
Liu F (2025). [PMID: 40938072](https://pubmed.ncbi.nlm.nih.gov/40938072/). *Invest Ophthalmol Vis Sci*. [Gene Therapy / Novel Therapeutics]
AbouZeid AA (2025). [PMID: 40340192](https://pubmed.ncbi.nlm.nih.gov/40340192/). *J Pediatr Urol*. [Other]
Shankar M (2025). [PMID: 40896634](https://pubmed.ncbi.nlm.nih.gov/40896634/). *Indian J Nephrol*. [Case Report / Case Series]
Shindo M (2024). [PMID: 38171880](https://pubmed.ncbi.nlm.nih.gov/38171880/). *Exp Anim*. [Basic Science / Preclinical]